Apnimed Secures $150 Million to Prepare for AD109's U.S. Launch Against Obstructive Sleep Apnea Apnimed has announced acquiring up to $150 million in debt financing aimed at supporting the U.S. launch of its innovative treatment for obstructive sleep apnea, AD109.

Apnimed Secures $150 Million to Prepare for AD109's U.S. Launch Against Obstructive Sleep Apnea #United_States #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed Sells Joint Venture Stake for $150 Million to Focus on AD109 Development Apnimed has sold its stake in a joint venture with Shionogi for $150M, strengthening its focus on the development of AD109 for obstructive sleep apnea.

Apnimed Sells Joint Venture Stake for $150 Million to Focus on AD109 Development #USA #Cambridge #Apnimed #AD109 #Shionogi

Apnimed Set to Showcase Innovative Solutions at LifeSci Summit in London Apnimed, Inc. announces its participation in the upcoming LifeSci Capital & Sofinnova Partners Growth and Innovation Summit, set for November 17.

Apnimed Set to Showcase Innovative Solutions at LifeSci Summit in London #United_States #Cambridge #Sleep_Disorders #Apnimed #OSA_Treatment

Apnimed's Sulthiame Shows Promising Phase 2 Results for Treating Obstructive Sleep Apnea Apnimed's Phase 2 trial of Sulthiame published in The Lancet shows significant efficacy in treating obstructive sleep apnea, with promising safety data.

Apnimed's Sulthiame Shows Promising Phase 2 Results for Treating Obstructive Sleep Apnea #United_States #Cambridge #Obstructive_Sleep_Apnea #Apnimed #Sulthiame

Apnimed to Showcase Phase 3 Data for Groundbreaking Sleep Apnea Treatment at CHEST 2025 Apnimed will present new Phase 3 data for AD109, an innovative oral medication for obstructive sleep apnea, at the CHEST 2025 meeting in Chicago.

Apnimed to Showcase Phase 3 Data for Groundbreaking Sleep Apnea Treatment at CHEST 2025 #United_States #Chicago #Obstructive_Sleep_Apnea #Apnimed #AD109

Apnimed Set to Present at the 5th Annual Needham Virtual Biotech Forum Apnimed, Inc. will participate in the Needham Private Biotech and MedTech Forum, showcasing its innovative oral treatments for sleep apnea.

Apnimed Set to Present at the 5th Annual Needham Virtual Biotech Forum #USA #Cambridge #Apnimed #OSA #Shionogi

Apnimed to Showcase Groundbreaking OSA Treatments at CHEST 2025 Annual Meeting Apnimed, Inc. will present innovative Phase 3 data for AD109 at the CHEST Annual Meeting, addressing urgent needs in obstructive sleep apnea.

Apnimed to Showcase Groundbreaking OSA Treatments at CHEST 2025 Annual Meeting #United_States #Chicago #Apnimed #OSA #AD109

Apnimed Set to Engage Investors at Key September Conferences Focused on Sleep Disorders Apnimed, Inc. announces its participation in upcoming investor conferences focusing on sleep-related disorders and pioneering oral treatments.

Apnimed Set to Engage Investors at Key September Conferences Focused on Sleep Disorders #United_States #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025 At the World Sleep Congress 2025, Apnimed will present its groundbreaking oral therapy, AD109, aimed at alleviating obstructive sleep apnea.

Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025 #United_States #Cambridge #Obstructive_Sleep_Apnea #Apnimed #AD109

Promising Results for Apnimed's AD109 in Obstructive Sleep Apnea Clinical Trials Apnimed's AD109 shows positive Phase 3 trial results for obstructive sleep apnea, offering hope for millions who need effective treatment options.

Promising Results for Apnimed's AD109 in Obstructive Sleep Apnea Clinical Trials #United_States #Cambridge #Apnimed #OSA #AD109

Exploring the Rapid Growth of the Sleep Apnea Market: Innovations and Insights The sleep apnea market is set to grow at a significant CAGR of 20% from 2020 to 2034. Learn more about current trends, therapies, and key players.

Exploring the Rapid Growth of the Sleep Apnea Market: Innovations and Insights #None #Eli_Lilly #Apnimed #Sleep_Apnea_Market

Apnimed's Upcoming Investor Conferences: Pioneering Sleep Apnea Treatments Apnimed, a clinical-stage pharmaceutical company, highlights its presence at major investor conferences in July, focusing on innovative sleep apnea treatments.

Apnimed's Upcoming Investor Conferences: Pioneering Sleep Apnea Treatments #United_States #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed to Showcase Innovative Findings on Obstructive Sleep Apnea at SLEEP 2025 Annual Meeting At the upcoming SLEEP 2025 annual meeting, Apnimed will unveil key presentations highlighting the burden of obstructive sleep apnea, promising newer treatment avenues.

Apnimed to Showcase Innovative Findings on Obstructive Sleep Apnea at SLEEP 2025 Annual Meeting #United_States #Seattle #Obstructive_Sleep_Apnea #Apnimed #SLEEP_2025

Apnimed Achieves Landmark Phase 3 Clinical Trial Results for AD109 in Obstructive Sleep Apnea Treatment Apnimed has reported promising results from its Phase 3 clinical trial of AD109, a new oral treatment for obstructive sleep apnea, marking a potential shift in patient care.

Apnimed Achieves Landmark Phase 3 Clinical Trial Results for AD109 in Obstructive Sleep Apnea Treatment #USA #Cambridge #Sleep_Apnea #Apnimed #AD109

Apnimed Prepares for Major Presentations at the 2025 ATS Conference on Sleep Medicine Innovations Apnimed, Inc. has announced multiple presentations at the upcoming ATS International Conference in San Francisco, showcasing advances in sleep medicine.

Apnimed Prepares for Major Presentations at the 2025 ATS Conference on Sleep Medicine Innovations #United_States #San_Francisco #Apnimed #AD109 #ATS2025

Apnimed Acquires Global Rights to Sulthiame for Sleep Disorders Treatment Apnimed expands its oral pharmacotherapy portfolio by acquiring global rights to sulthiame, targeting obstructive sleep apnea and more. This innovative approach seeks to reshape treatment pathways.

Apnimed Acquires Global Rights to Sulthiame for Sleep Disorders Treatment #United_States #Cambridge #Sleep_Apnea #Apnimed #Sulthiame

Apnimed Announces Breakthrough in Sleep Apnea Treatment with Clinical Updates on SASS-001 and AD109 Trials Apnimed has made significant strides in sleep apnea treatment, with updates on SASS-001 and AD109 trials, promising new options for patients.

Apnimed Announces Breakthrough in Sleep Apnea Treatment with Clinical Updates on SASS-001 and AD109 Trials #United_States #Cambridge #Apnimed #SASS-001 #AD109

Apnimed to Showcase Innovations at the 24th Needham Virtual Healthcare Conference Apnimed, Inc. will be participating in the 24th Annual Needham Virtual Healthcare Conference, presenting new advancements in oral therapies for sleep-related disorders.

Apnimed to Showcase Innovations at the 24th Needham Virtual Healthcare Conference #USA #healthcare #Cambridge #Apnimed #OSA

Apnimed Welcomes Kevin R. Lind as Non-Executive Chairman of the Board Apnimed has appointed Kevin R. Lind as its new non-executive chairman. His expertise is expected to play a key role in the company's growth amid upcoming clinical trials.

Apnimed Welcomes Kevin R. Lind as Non-Executive Chairman of the Board #United_States #Cambridge #Apnimed #Kevin_Lind #OSA